NBT Bank N A NY Sells 65 Shares of Amgen Inc. $AMGN

NBT Bank N A NY trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 1.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,608 shares of the medical research company’s stock after selling 65 shares during the period. NBT Bank N A NY’s holdings in Amgen were worth $1,566,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of AMGN. REAP Financial Group LLC lifted its holdings in shares of Amgen by 201.6% during the 2nd quarter. REAP Financial Group LLC now owns 184 shares of the medical research company’s stock worth $51,000 after acquiring an additional 123 shares during the last quarter. Sax Wealth Advisors LLC lifted its holdings in shares of Amgen by 20.9% during the 2nd quarter. Sax Wealth Advisors LLC now owns 1,254 shares of the medical research company’s stock worth $350,000 after acquiring an additional 217 shares during the last quarter. DMC Group LLC lifted its holdings in shares of Amgen by 1.2% during the 2nd quarter. DMC Group LLC now owns 3,669 shares of the medical research company’s stock worth $1,024,000 after acquiring an additional 44 shares during the last quarter. BankPlus Trust Department lifted its holdings in shares of Amgen by 41.6% during the 2nd quarter. BankPlus Trust Department now owns 11,663 shares of the medical research company’s stock worth $3,256,000 after acquiring an additional 3,425 shares during the last quarter. Finally, Independent Solutions Wealth Management LLC lifted its holdings in shares of Amgen by 3.9% during the 2nd quarter. Independent Solutions Wealth Management LLC now owns 9,335 shares of the medical research company’s stock worth $2,606,000 after acquiring an additional 348 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen Stock Down 0.3%

NASDAQ AMGN opened at $294.62 on Thursday. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $335.88. The stock has a market capitalization of $158.61 billion, a PE ratio of 24.09, a PEG ratio of 2.57 and a beta of 0.49. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. The business’s 50-day moving average is $286.90 and its 200 day moving average is $287.93.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, beating analysts’ consensus estimates of $5.28 by $0.74. The business had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.Amgen’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Sell-side analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were given a dividend of $2.38 per share. The ex-dividend date of this dividend was Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a yield of 3.2%. Amgen’s dividend payout ratio is presently 77.84%.

Insider Buying and Selling

In other news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the sale, the senior vice president owned 7,209 shares of the company’s stock, valued at approximately $2,141,000.91. The trade was a 14.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.76% of the stock is owned by insiders.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of research analyst reports. Bank of America lifted their price objective on shares of Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a report on Friday, September 26th. Morgan Stanley boosted their price target on shares of Amgen from $330.00 to $333.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. William Blair restated an “outperform” rating on shares of Amgen in a research report on Tuesday, June 24th. Raymond James Financial started coverage on Amgen in a report on Wednesday, September 3rd. They issued a “market perform” rating on the stock. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $305.00 target price on shares of Amgen in a report on Tuesday, June 24th. Eight research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $309.42.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.